JP2006513208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513208A5 JP2006513208A5 JP2004563592A JP2004563592A JP2006513208A5 JP 2006513208 A5 JP2006513208 A5 JP 2006513208A5 JP 2004563592 A JP2004563592 A JP 2004563592A JP 2004563592 A JP2004563592 A JP 2004563592A JP 2006513208 A5 JP2006513208 A5 JP 2006513208A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- occurrence
- optionally substituted
- nrco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 84
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 48
- 229910052760 oxygen Inorganic materials 0.000 claims 30
- 229910052717 sulfur Inorganic materials 0.000 claims 30
- 229910052757 nitrogen Inorganic materials 0.000 claims 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000005842 heteroatom Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 19
- 239000001301 oxygen Substances 0.000 claims 19
- 239000011593 sulfur Substances 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- -1 nitro-substituted pyrazole Chemical class 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000001931 aliphatic group Chemical group 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 10
- 125000002950 monocyclic group Chemical group 0.000 claims 10
- 125000006413 ring segment Chemical group 0.000 claims 10
- 125000001118 alkylidene group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 102000001332 SRC Human genes 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002723 alicyclic group Chemical group 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 108010087686 src-Family Kinases Proteins 0.000 claims 2
- 125000003363 1,3,5-triazinyl group Chemical class N1=C(N=CN=C1)* 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005750 substituted cyclic group Chemical group 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CCC*c1nnc(cc2)[n]1nc2SC1CC1 Chemical compound CCC*c1nnc(cc2)[n]1nc2SC1CC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43512402P | 2002-12-18 | 2002-12-18 | |
| US60/435,124 | 2002-12-18 | ||
| PCT/US2003/039990 WO2004058769A2 (en) | 2002-12-18 | 2003-12-17 | Triazolopyridazines as protein kinases inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006513208A JP2006513208A (ja) | 2006-04-20 |
| JP2006513208A5 true JP2006513208A5 (enExample) | 2007-01-25 |
| JP4817661B2 JP4817661B2 (ja) | 2011-11-16 |
Family
ID=32682164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563592A Expired - Fee Related JP4817661B2 (ja) | 2002-12-18 | 2003-12-17 | プロテインキナーゼインヒビターとしてのトリアゾロピリダジン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7268136B2 (enExample) |
| EP (1) | EP1575959B1 (enExample) |
| JP (1) | JP4817661B2 (enExample) |
| KR (1) | KR101075812B1 (enExample) |
| CN (1) | CN100567296C (enExample) |
| AT (1) | ATE473980T1 (enExample) |
| AU (1) | AU2003297161B8 (enExample) |
| CA (1) | CA2510534C (enExample) |
| DE (1) | DE60333387D1 (enExample) |
| MX (1) | MXPA05006478A (enExample) |
| NO (1) | NO20053470L (enExample) |
| NZ (1) | NZ541151A (enExample) |
| RU (1) | RU2005122484A (enExample) |
| WO (1) | WO2004058769A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171062A1 (en) * | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
| AU2003272548A1 (en) * | 2002-09-16 | 2004-04-30 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
| US7824872B2 (en) * | 2003-04-03 | 2010-11-02 | Theravalues Corporation | Pharmaceutical agents |
| FR2876584B1 (fr) * | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| AU2006302174B2 (en) * | 2005-10-06 | 2013-06-20 | Exelixis, Inc. | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 |
| UA98297C2 (en) | 2005-12-21 | 2012-05-10 | Янссен Фармацевтика, Н.В. | Triazolopyridazines as tyrosine kinase modulators |
| JP2009538899A (ja) * | 2006-05-30 | 2009-11-12 | ファイザー・プロダクツ・インク | トリアゾロピリダジン誘導体 |
| WO2008021781A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| US8481538B2 (en) * | 2006-09-18 | 2013-07-09 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of c-Met and uses thereof |
| KR20090071612A (ko) * | 2006-10-23 | 2009-07-01 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 단백질 키나제 조정제로서의 바이시클릭 트리아졸 |
| US7750007B2 (en) * | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| CA2669991C (en) | 2006-11-22 | 2016-01-26 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| CA2685106A1 (en) | 2007-04-25 | 2008-11-06 | Exelixis, Inc. | 6-phenylpyrimidinones as pim modulators |
| US8188083B2 (en) | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| KR20090031122A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물 |
| CN101878219B (zh) | 2007-09-27 | 2014-04-02 | 西班牙国家癌症研究中心 | 用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类 |
| CA2724742C (en) | 2008-05-21 | 2016-07-19 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US8987251B2 (en) | 2008-08-19 | 2015-03-24 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| US8895550B2 (en) | 2008-08-19 | 2014-11-25 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| TWI496779B (zh) * | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
| CA2751517A1 (en) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| HUE027964T2 (en) | 2009-04-02 | 2016-11-28 | Fund Centro Nac De Investig Oncologicas Carlos Iii | Imidazo [2,1-b] [1,3,4] thiadiazole derivatives |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| ES2608329T3 (es) | 2010-02-03 | 2017-04-07 | Incyte Holdings Corporation | Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012098387A1 (en) * | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| AU2012254082B2 (en) | 2011-02-25 | 2016-12-08 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| WO2012125667A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| EP2702063A1 (en) * | 2011-04-29 | 2014-03-05 | Amgen Inc. | Bicyclic pyridazine compounds as pim inhibitors |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| WO2013004984A1 (en) * | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| ES2834093T3 (es) | 2011-07-21 | 2021-06-16 | Sumitomo Dainippon Pharma Oncology Inc | Inhibidores de proteína quinasa heterocíclicos |
| CA2848518C (en) | 2011-09-27 | 2019-06-18 | Genfit | Derivatives of 6-substituted triazolopyridazines as rev-erb agonists |
| WO2013166276A1 (en) * | 2012-05-02 | 2013-11-07 | Southern Research Institute | Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
| WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| CN102938491B (zh) * | 2012-09-28 | 2014-12-10 | 华为终端有限公司 | 天线、组合天线和移动终端 |
| JP2016510039A (ja) * | 2013-02-28 | 2016-04-04 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法 |
| GB201321745D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| PT3157928T (pt) | 2014-06-20 | 2019-05-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida |
| CN109651253B (zh) * | 2017-10-12 | 2022-03-25 | 上海医药工业研究院 | 苯丙烯酸酯衍生物及其作为神经保护药物的应用 |
| CN108498512A (zh) * | 2018-04-22 | 2018-09-07 | 于志国 | 一种治疗心力衰竭的药物组合物及其制备方法和用途 |
| CN109045036B (zh) * | 2018-07-19 | 2020-10-02 | 中山大学 | [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用 |
| HUE072069T2 (hu) | 2019-02-12 | 2025-10-28 | Sumitomo Pharma America Inc | 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2153902A1 (de) * | 1971-10-29 | 1973-05-03 | Boehringer Mannheim Gmbh | Antimikrobiell wirksame nitrofuranderivate und verfahren zur herstellung derselben |
| DE2215999B2 (de) * | 1972-04-01 | 1977-10-20 | Boehnnger Mannheim GmbH, 6800 Mannheim | 3-(5-nitro-2-imidazolyl)-s-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und arzneimittel |
| DE2254783A1 (de) * | 1972-04-01 | 1974-05-16 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| DE2261735A1 (de) * | 1972-04-01 | 1974-06-20 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| DE2261693A1 (de) * | 1972-04-01 | 1974-06-20 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| PL91799B1 (enExample) * | 1972-04-01 | 1977-03-31 | ||
| DE2418435A1 (de) * | 1974-04-17 | 1975-10-30 | Boehringer Mannheim Gmbh | Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung |
| FR2668151A1 (fr) * | 1990-10-23 | 1992-04-24 | Rhone Poulenc Agrochimie | Composes a groupe triazolopyridazine leurs preparations et compositions herbicides les contenant. |
| IL127911A0 (en) * | 1996-07-25 | 1999-11-30 | Merck Sharp & Dohme | Substituted triazolo-pyridazine derivatives as ligands for gaba receptors |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| DE10038019A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
| WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| AU2002251266A1 (en) | 2001-04-10 | 2002-10-28 | Merck Sharp And Dohme Limited | Inhibitors of akt activity |
| JP4385620B2 (ja) * | 2002-03-01 | 2009-12-16 | アステラス製薬株式会社 | 含窒素複素環化合物 |
| CA2476757A1 (en) | 2002-03-01 | 2003-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compound |
-
2003
- 2003-12-17 NZ NZ541151A patent/NZ541151A/en unknown
- 2003-12-17 US US10/738,956 patent/US7268136B2/en not_active Expired - Fee Related
- 2003-12-17 EP EP03814020A patent/EP1575959B1/en not_active Expired - Lifetime
- 2003-12-17 JP JP2004563592A patent/JP4817661B2/ja not_active Expired - Fee Related
- 2003-12-17 KR KR1020057011467A patent/KR101075812B1/ko not_active Expired - Fee Related
- 2003-12-17 CN CNB2003801091296A patent/CN100567296C/zh not_active Expired - Fee Related
- 2003-12-17 AT AT03814020T patent/ATE473980T1/de not_active IP Right Cessation
- 2003-12-17 RU RU2005122484/04A patent/RU2005122484A/ru not_active Application Discontinuation
- 2003-12-17 CA CA2510534A patent/CA2510534C/en not_active Expired - Fee Related
- 2003-12-17 AU AU2003297161A patent/AU2003297161B8/en not_active Ceased
- 2003-12-17 DE DE60333387T patent/DE60333387D1/de not_active Expired - Lifetime
- 2003-12-17 WO PCT/US2003/039990 patent/WO2004058769A2/en not_active Ceased
- 2003-12-17 MX MXPA05006478A patent/MXPA05006478A/es active IP Right Grant
-
2005
- 2005-07-15 NO NO20053470A patent/NO20053470L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513208A5 (enExample) | ||
| CA2510534A1 (en) | Compositions useful as inhibitors of protein kinases | |
| JP6231226B2 (ja) | ピロリジン−２，５−ジオン誘導体、医薬組成物およびｉｄｏ１阻害剤としての使用のための方法 | |
| JP5726190B2 (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| EP1183252B1 (en) | pharmaceutically active compounds | |
| JP6891286B2 (ja) | チューブリン阻害剤 | |
| CN103221412B (zh) | (氮杂)中氮茚衍生物及其药物用途 | |
| JP2010510215A5 (enExample) | ||
| JP2006509719A5 (enExample) | ||
| JPWO1999059999A1 (ja) | ｓＰＬＡ２阻害作用を有するピロロ［１，２−ｂ］ピリダジン誘導体 | |
| RU2005128190A (ru) | Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации | |
| JP2013532652A5 (enExample) | ||
| CN103080107A (zh) | 作为蛋白激酶抑制剂的杂芳基化合物和组合物 | |
| TW201212905A (en) | 1,5-diphenyl-penta-1,4-dien-3-one compounds | |
| EP2723340A1 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| KR20170031786A (ko) | 다발성 골수종을 치료하기 위한 약물 병용물 | |
| JPH0558894A (ja) | 抗腫瘍剤 | |
| JP2010510216A5 (enExample) | ||
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| CN110437119B (zh) | 一种n-取代含氮杂环衍生物及其制备方法与应用 | |
| JPH0543698B2 (enExample) | ||
| CN117050066B (zh) | 2-苯并噁唑酮类衍生物及其制备方法和应用 | |
| CN111718350A (zh) | 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用 | |
| KR20230143611A (ko) | 바이사이클릭 고리를 포함하는 tyk2 억제제 화합물 | |
| MX2015000797A (es) | Uso de inhibidores de vegfr-3 para tratar carcinoma hepatocelular. |